- Home
- OXSQ vs NKTX Comparison
OXSQ vs NKTX Comparison
Compare OXSQ & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- NKTX
- Stock Information
- Founded
- OXSQ 2003
- NKTX 2015
- Country
- OXSQ United States
- NKTX United States
- Employees
- OXSQ N/A
- NKTX N/A
- Industry
- OXSQ Blank Checks
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- NKTX Health Care
- Exchange
- OXSQ Nasdaq
- NKTX Nasdaq
- Market Cap
- OXSQ 150.6M
- NKTX 123.5M
- IPO Year
- OXSQ N/A
- NKTX 2020
- Fundamental
- Price
- OXSQ $1.75
- NKTX $2.30
- Analyst Decision
- OXSQ
- NKTX Strong Buy
- Analyst Count
- OXSQ 0
- NKTX 5
- Target Price
- OXSQ N/A
- NKTX $13.50
- AVG Volume (30 Days)
- OXSQ 1.3M
- NKTX 1.2M
- Earning Date
- OXSQ 11-04-2025
- NKTX 11-06-2025
- Dividend Yield
- OXSQ 24.00%
- NKTX N/A
- EPS Growth
- OXSQ N/A
- NKTX N/A
- EPS
- OXSQ N/A
- NKTX N/A
- Revenue
- OXSQ $40,243,556.00
- NKTX N/A
- Revenue This Year
- OXSQ N/A
- NKTX N/A
- Revenue Next Year
- OXSQ N/A
- NKTX N/A
- P/E Ratio
- OXSQ N/A
- NKTX N/A
- Revenue Growth
- OXSQ N/A
- NKTX N/A
- 52 Week Low
- OXSQ $1.56
- NKTX $1.31
- 52 Week High
- OXSQ $2.96
- NKTX $4.55
- Technical
- Relative Strength Index (RSI)
- OXSQ 44.80
- NKTX 53.68
- Support Level
- OXSQ $1.64
- NKTX $2.11
- Resistance Level
- OXSQ $1.94
- NKTX $2.74
- Average True Range (ATR)
- OXSQ 0.08
- NKTX 0.18
- MACD
- OXSQ 0.04
- NKTX 0.03
- Stochastic Oscillator
- OXSQ 56.58
- NKTX 39.58
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.